Rituximab monotherapy in mild pemphigus

J Dermatolog Treat. 2022 May;33(3):1784-1786. doi: 10.1080/09546634.2020.1836309. Epub 2020 Oct 25.

Authors

Ali Nili¹, Hamidreza Mahmoudi¹, Nikta Heidari¹, Soheil Tavakolpour^{1

2}, Ali Salehi Farid¹, Kamran Balighi¹, Maryam Daneshpazhooh¹

Affiliations

¹ Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran.
² Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

PMID: 33040641
DOI: 10.1080/09546634.2020.1836309

No abstract available

Publication types

Letter

MeSH terms

Humans
Immunologic Factors / therapeutic use
Pemphigus* / drug therapy
Remission Induction
Rituximab / therapeutic use
Treatment Outcome

Substances

Immunologic Factors
Rituximab